Evaluation of the Vp22 Gene Adjuvant for Enhancement of Dna Vaccine Against Somatostatin in Mice

Li. Han,A. X. Liang,J. Zhang,M. Fang,G. H. Hua,L. Sang,L. Y. Geng,H. R. Wang,L. G. Yang
DOI: https://doi.org/10.1017/s175173110800284x
IF: 3.73
2008-01-01
animal
Abstract:Somatostatin (SS) is a hormone that inhibits the secretion of growth hormone. Immunization against SS can promote the growth of animals. A novel SS-VP22 fused vaccine, pEGS2SS-V, was constructed from pEGS2SS plasmid with a VP22 gene fragment. Two times of immunization with pEGS2SS-V-induced anti-SS antibodies in mice. Compared with mice immunized with pEGS2SS and 0.85% saline, the growth performance of mice immunized with pEGS2SS-V was increased by 14.1% (P < 0.05) and 48.4% (P < 0.01) on the 2nd week after the first vaccination, respectively. The results indicated that the effects of the somatostatin DNA vaccine could be improved effectively by VP22 gene adjuvant.
What problem does this paper attempt to address?